NEW YORK (TheStreet) -- GlaxoSmithKline shares are climbing, up 0.5% to $48.91 on Thursday, following reports in theaGuardianathat the National Institute of Allergy and Infectious Diseases will be holding a press conference today to announce that an Ebola vaccine developed by the drug manufacturer will begin human trials in the U.K. in the coming weeks. GlaxoSmithKline will be working with the World Health Organization to distribute the vaccine to help combat an Ebola virusaoutbreak in West Africa if the trials are successful. Must Read: Warren Buffett's 25 Favorite Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings team rates GLAXOSMITHKLINE PLC as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation: "We rate GLAXOSMITHKLINE PLC (GSK) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income." Highlights from the analysis by TheStreet Ratings Team goes as follows: You can view the full analysis from the report here: GSK Ratings Report GSK data by YCharts EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.
Click to view a price quote on GSK. Click to research the Drugs industry.
from Latest TSC Headlines http://ift.tt/1sImCl1
No comments:
Post a Comment